SUPPORTING INFECTIOUS DISEASE RESEARCH

Vector pMCSG53 Containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Non-Structural Protein 9 Gene

Catalog No. NR-52424

This reagent is the tangible property of the U.S. Government.

Product Description:

The non-structural protein 9 (nsp9) gene from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: <u>MN908947</u>) was codon optimized and cloned into the pMCSG53 plasmid. pMCSG53 is an *Escherichia coli (E. coli)* expression vector that contains an N-terminal hexa-histidine tag, followed by a tobacco etch virus (TEV) protease recognition site prior to the insert coding sequence, resulting in the expression of a cleavable histidine-tagged protein. It also contains tRNA genes covering rare codons for Arg (AGG/AGA) and Ile (AUA) to improve expression in *E. coli*. The beta-lactamase gene, *bla*, provides transformant selection through ampicillin resistance in *E. coli*. The deposited plasmid was transformed into One ShotTM TOP10 *Escherichia coli* (InvitrogenTM C404003), grown in Luria-Bertani broth with ampicillin (50 µg per mL) for 1 day at 37°C in an aerobic atmosphere, extracted using a Plasmid *Plus* Maxi Kit (QIAGEN[®] 12963) and vialed in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

Lot: 70035116

Manufacturing Date: 06MAY2020

TEST	SPECIFICATIONS	RESULTS
Next-Generation DNA Sequencing	~ 5150 base pairs	5150 base pairs ¹
Genotypic Analysis		
Sequencing of nsp9 insert (~ 350 base pairs)	100% sequence identity to depositor's sequence	100% sequence identity to depositor's sequence ²
N-terminal His₀ tag	His ₆ tag sequence confirmed	His ₆ tag sequence confirmed
N-terminal TEV protease site	TEV protease site sequence confirmed	TEV protease site sequence confirmed
Antibiotic Resistance		
Ampicillin (encoded by beta-lactamase gene <i>bla</i>) ³	bla sequence present	bla sequence present
Concentration by PicoGreen [®] Measurement	≥ 2 µg/mL	0.2 μg in 30 μL per vial (7 μg/mL)
Amount per Vial	Report results	0.2 μg per vial
OD ₂₆₀ /OD ₂₈₀ Ratio (pre-vial)	1.7 to 2.1	2.0
Effective Bacterial Transformation Invitrogen™ One Shot™ TOP10 Escherichia coli	≥ 50 colonies per ng	240 colonies per ng

¹The sequence was assembled pre-vial using the depositor's predicted sequence as the reference sequence. The complete plasmid sequence and map are provided on the BEI Resources webpage.

²The NR-52432 insert was codon optimized, but is consistent with the SARS-CoV-2, Wuhan-Hu-1 nsp9 protein (GenPept: YP_009725305.1).

³The antibiotic ampicillin degrades quickly during growth. Bacterial stationary phase should be minimized during plasmid expansion to avoid plasmid loss and increased antibiotic concentrations may be necessary.

/Heather Couch/ Heather Couch

24 AUG 2020

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC[®] and the contributor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.



ATCC[®] is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898